Shares of Moderna Inc. (NASDAQ:MRNA) are trading higher Tuesday morning, as Wall Street analysts upgrade their ratings following landmark Phase 3 oncology data.
Wolfe Research upgraded Moderna Tuesday morning, following a similar move by BofA Securities last week to raise its price target to $170.
Moderna stock is showing upward bias. What should traders watch with MRNA?
Phase 3 Melanoma Trial Meets Primary Endpoints With Partner Merck
Underpinning the bullish sentiment is a major clinical milestone announced on Aug. 19, alongside partner Merck & Co Inc. (NYSE:MRK).
